Rheumatoid vasculitis treated with infliximab.

Abstract

We describe a patient with rheumatoid vasculitis (RV) who showed a good response to anti-tumor necrosis factor-a therapy. TNF-a antagonists should be considered as treatment in systemic RV, especially in patients who do not respond to immunosuppressive drugs or who have contraindication for such treatment.

• Authors: A Egon van der Bijl, Cornelia F Allaart, Jeroen Van Vugt, Sjoerd Van Duinen, Ferdinand C Breedveld
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 32 Issue 8 Pg. 1607-9 (Aug 2005) ISSN: 0315-162X [Print] Canada
• PMID: 16078342 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Humans
• Infliximab
• Male
• Rheumatic Diseases (complications, drug therapy, pathology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Vasculitis (drug therapy, etiology, pathology)